MHC-II Signature Correlates With Anti-Tumor Immunity and Predicts anti-PD-L1 Response of Bladder Cancer

MHC-II Signature Correlates With Anti-Tumor Immunity and Predicts anti-PD-L1 Response of Bladder Cancer

A large proportion of anti-tumor immunity research is focused on major histocompatibility complex class I (MHC-I) molecules and CD8+ T cells. Despite mounting evidence has shown that CD4+ T cells play a major role in anti-tumor immunity, the role of the MHC-II molecules in tumor immunotherapy has no...

Full description

Bibliographic Details
Main Authors: Ruibin Yi, Shuo Hong, Yueming Zhang, Anqi Lin, Haoxuan Ying, Weidong Zou, Qiongyao Wang, Ting Wei, Quan Cheng, Weiliang Zhu, Peng Luo, Jian Zhang
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-02-01
Series:Frontiers in Cell and Developmental Biology
Subjects:
MHC-II signature
immune checkpoint inhibitor
immune response
prognosis
bladder cancer
Online Access:https://www.frontiersin.org/articles/10.3389/fcell.2022.757137/full

Internet

https://www.frontiersin.org/articles/10.3389/fcell.2022.757137/full

Similar Items